Larry J Dumont
Overview
Explore the profile of Larry J Dumont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
1512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kelly K, Kanias T, Leite C, Stanley C, Dumont L
Transfusion
. 2024 Dec;
65(1):185-193.
PMID: 39673312
Background: Evaluation of additive solutions, storage containers, new collection and storage methods, and other potential modifications is resource intensive, resulting in diversion of platelets away from blood bank inventories and...
2.
Dumont L, Kelly K, Nemkov T, Leite C, Gresens C, Stanley C, et al.
Transfusion
. 2024 Nov;
64(12):2405-2409.
PMID: 39552144
Background: Pathogen reduction technology (PRT)-treated apheresis platelets (APs) were returned without platelet swirl and with pH < 6.2. The platelet donor was taking prescription levothyroxine and metformin plus over-the-counter medications...
3.
Vandenbroeke T, Gloor C, Wingfield T, Leite C, Carr K, Turner C, et al.
Transfusion
. 2023 Nov;
64(1):132-140.
PMID: 37991217
Background: Increasing the number of collections of whole blood-derived platelets (WBDP) and lengthening the allowable storage time may alleviate platelet (PLT) shortages. There is a need for new PLT pooling...
4.
Janoff E, Brown S, Belitskaya-Levy I, Curtis J, Bonomo R, Miller E, et al.
Contemp Clin Trials Commun
. 2023 Aug;
35:101190.
PMID: 37560085
Background: Effective therapeutics for severe acute respiratory syndrome CoronaVirus-2 (SARS-CoV-2) infection are evolving. Under Emergency Use Authorization, COVID-19 convalescent plasma (CCP) was widely used in individuals hospitalized for COVID-19, but...
5.
Dumont L, Wolfe B, Leite C, Moss R, Wegener C, Thompson K, et al.
Transfusion
. 2023 Jun;
63(8):1554-1562.
PMID: 37358313
Background: Manufacturing methods for dimethyl sulfoxide (DMSO)-cryopreserved platelets (CPPs) are manual and labor intensive. Thawing and prepare-for-transfusion steps are in an open system that requires transfusion within 4 h. A...
6.
Esparza O, Hernandez G, Rojas-Sanchez G, Calzada-Martinez J, Nemkov T, Kelher M, et al.
Blood Transfus
. 2023 May;
PMID: 37235734
Background: The collection of the first blood flow into a diversion pouch (DP) has become widely adopted in blood donation systems to reduce whole-blood unit contamination from skin bacteria. The...
7.
McDyer J, Azimpouran M, Durkalski-Mauldin V, Clevenger R, Yeatts S, Deng X, et al.
JCI Insight
. 2023 Mar;
8(8).
PMID: 36862515
Multiple randomized, controlled clinical trials have yielded discordant results regarding the efficacy of convalescent plasma in outpatients, with some showing an approximately 2-fold reduction in risk and others showing no...
8.
Levine A, Fukuta Y, Huaman M, Ou J, Meisenberg B, Patel B, et al.
Clin Infect Dis
. 2023 Feb;
76(12):2077-2086.
PMID: 36809473
Background: Outpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma...
9.
Levine A, Fukuta Y, Huaman M, Ou J, Meisenberg B, Patel B, et al.
medRxiv
. 2022 Dec;
PMID: 36561181
Background: Monoclonal antibody and antiviral treatments for COVID-19 disease remain largely unavailable worldwide, and existing monoclonal antibodies may be less active against circulating omicron variants. Although treatment with COVID-19 convalescent...
10.
Helander L, McKinney C, Kelly K, Mack S, Sanders M, Gurley J, et al.
Front Immunol
. 2022 Sep;
13:994321.
PMID: 36081507
Chronic granulomatous disease (CGD) with McLeod neuroacanthocytosis syndrome (MLS) is a contiguous gene deletion disorder characterized by defective phagocytic function and decreased Kell antigen expression. CGD cure is achieved through...